Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05512949 · ClinicalTrials.gov registry record · Phase 2
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
A Phase 2 study of Monkeypox, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
- 8
- Study locations
NCT05512949: Completed Phase 2 study of Monkeypox, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT05512949 is a Phase 2 study of Monkeypox that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 229 participants, roughly in line with the 215-participant average among 3 other Monkeypox trials with a reported enrollment target. The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05512949, a Phase 2 study of Monkeypox, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study is a Phase 2 randomized, open-label, non-placebo controlled, multi-site clinical trial that will evaluate two intradermal (ID) regimens for Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine compared to the standard subcutaneous (SC) regimen in healthy, vaccinia-naïve adults 18 to 50 years of age, inclusive. At least 210 participants will be enrolled and randomized to one of three study arms. The two dose sparing strategies include one-fifth (2 x 10\^7) and one-tenth (1 x 10\^7) of the standard dose of MVA-BN administered ID on Day 1 and 29 (Arm 1 and 2, respectively). The comparator arm (Arm 3) will be the 2-dose standard (1 x 10\^8) MVA-BN SC regimen. The study will enroll a 1:1:1 randomization allocation. Participants will not be stratified by clinical trial site, demographic characteristics or human immunodeficiency virus (HIV) infection status; however, these data will be collected during screening and enrollment. Each participant may be screened either in a separate visit in the 7 days prior to Day 1 or on Day 1. The primary hypothesis involves a two-step hierarchical process. The study will first test non-inferiority of the 2 x 10\^7 ID regimen relative to 1 x 10\^8 SC (standard dose regimen). If the 2 x 10\^7 ID regimen is non-inferior to the standard dose regimen, hypothesis testing will proceed to test non-inferiority of the 1 x 10\^7 ID regimen relative to the standard dose regimen. The primary objectives are: 1) to determine if peak humoral immune responses following an ID regimen of 2 x 10\^7 50% Tissue Culture Infectious Dose (TCID50) MVA-BN are non-inferior to the licensed regimen of 1 x 10\^8 MVA-BN administered SC; 2) to determine if peak humoral immune responses following an ID regimen of 1 x 10\^7 TCID50 MVA-BN are non-inferior to the licensed regimen of 1 x 10\^8 MVA-BN administered SC.
Primary Outcome
Venous blood was collected at Study Day 43 and the serum was analyzed via the PRNT assay to determine if GMT of the intradermal regimen of 2 x 10\^7 TCID50 MVA-BN and 1 x 10\^7 TCID50 MVA- BN were non-inferior to that of the licensed regimen of 1 x 10\^8 TCID50 MVA-BN administered subcutaneously.
Conditions Studied
Interventions
- BIOLOGICAL JYNNEOS
Study Locations (8)
California
- University of California, San Diego (UCSD) - Antiviral Research Center (AVRC) - San Diego
District of Columbia
- George Washington University Medical Faculty Associates - Washington D.C.
Georgia
- The Hope Clinic of Emory University - Decatur
Maryland
- NIH Clinical Research Center, Investigational Drug Management and Research Section - Bethesda
Massachusetts
- Brigham and Women's Hospital - Boston
Missouri
- Saint Louis University Center for Vaccine Development - St Louis
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2022-09-09 |
| Est. Completion | 2025-02-24 |
| Phase | Phase 2 |
What the finished NCT05512949 record still lists
NCT05512949 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 215-participant average among 3 other Monkeypox trials with a reported enrollment target.
The record links to 1 condition, with Monkeypox appearing as the primary indexed condition, and to 1 intervention - of which JYNNEOS is the first listed.
NCT05512949 lists 8 locations in 8 states (California, District of Columbia, Georgia).
Frequently Asked Questions
What is clinical trial NCT05512949 about?
NCT05512949 is a clinical study titled "Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine". This study is a Phase 2 randomized, open-label, non-placebo controlled, multi-site clinical trial that will evaluate two intradermal (ID) regimens for Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine compared to the standard subcutaneous (SC) regimen in healthy, vaccinia-naïve adults 18 to ...
What is the current status of trial NCT05512949?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2022-09-09. Estimated completion is 2025-02-24.
What conditions does trial NCT05512949 study?
This clinical trial studies the following conditions: Monkeypox.
What interventions are being tested in trial NCT05512949?
The interventions under investigation include: JYNNEOS (BIOLOGICAL).
Who is sponsoring clinical trial NCT05512949?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05512949 being conducted?
This trial has 8 study locations across California, District of Columbia, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Monkeypox
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
COMPLETED · Phase 2
-
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
RECRUITING
-
A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI